R Squared’s Madrigal Pharmaceuticals MDGL Stock Holding History

R Squared’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,619	Closed	-$743K	–	640
2025 Q3	$743K	Sell	1,619 -151	-9%	-$56.3K	0.32%	74
2025 Q2	$536K	Buy	+1,770	New	+$527K	0.3%	94

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

R Squared's MDGL Position: Q4 2025 in Review

R Squared sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2025, closing a stake of 1,619 shares — an estimated $743K sold.

R Squared first reported a position in MDGL in Q2 2025 and held it in 2 quarters. The position peaked at $743K in Q3 2025. 387 funds tracked by Wall St. Rank hold MDGL as of Q4 2025.

R Squared reported no remaining Madrigal Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
R Squared sold 1,619 Madrigal Pharmaceuticals shares in Q4 2025, an estimated $743K.
R Squared first reported a position in Madrigal Pharmaceuticals in Q2 2025 and held it in 2 quarters.
R Squared's Madrigal Pharmaceuticals position peaked at $743K in Q3 2025.
387 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2025.

Based on R Squared's 13F filing for Q4 2025, filed 30 Jan 2026.